Drug guidance
Durvalumab with or without olaparib for treating primary advanced or recurrent endometrial cancer
Condition
Cancer
Gynaecological
16 September 2025
-
Published on 16 Sep 2025
Last Updated on 16 Sep 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended durvalumab in combination with platinum-based chemotherapy, then as maintenance with or without olaparib, for inclusion on the MOH List of Subsidised Drugs for patients with untreated primary advanced or recurrent endometrial cancer. The decision was based on the uncertainties surrounding the magnitude of clinical benefit compared with chemotherapy, and unfavourable cost-effectiveness compared with chemotherapy and dostarlimab.
Clinical indication, subsidy class and MediShield Life claim limit for durvalumab and olaparib are provided in the Annex.